Renal Cancer
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study.
December 10, 2024
Increased spatial coupling of integrin and collagen IV in the immunoresistant clear-cell renal-cell carcinoma tumor microenvironment.
December 9, 2024
Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?
December 6, 2024
Retrograde aortic dissection encountered amidst nephrectomy for renal cell carcinoma with IVC thrombus - a case report.
December 6, 2024
Predictive nomogram for ischemic stroke risk in clear cell renal cell carcinoma patients.
December 5, 2024
Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical Trials.
December 4, 2024
Renal cell carcinoma with inferior vena cava thrombus: Survival and prognostic factors in surgically treated patients.
December 3, 2024
STAT2/SLC27A3/PINK1-Mediated Mitophagy Remodeling Lipid Metabolism Contributes to Pazopanib Resistance in Clear Cell Renal Cell Carcinoma.
December 2, 2024
Late Survival and Long-Term Follow-Up After Radical Resection of Advanced Renal Cell Carcinoma With Associated Venous Tumor Thrombus.
December 2, 2024
Comparison of outcomes between single-port and multi-port robotic radical nephrectomy.
November 29, 2024
Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland.
November 29, 2024
Primary resistance to nivolumab plus ipilimumab therapy affects second-line treatment outcomes in patients with metastatic renal cell carcinoma.
November 28, 2024
Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study.
November 27, 2024